US 12,344,840 B2
Compositions of asymmetric interfering RNA and uses thereof
Chiang Jia Li, Cambridge, MA (US); Xiangao Sun, Brookline, MA (US); Harry Rogoff, Norwood, MA (US); and Youzhi Li, Westwood, MA (US)
Assigned to 1GLOBE HEALTH INSTITUTE LLC, Norwood, MA (US)
Filed by 1GLOBE HEALTH INSTITUTE LLC, Norwood, MA (US)
Filed on Apr. 22, 2021, as Appl. No. 17/237,856.
Application 15/081,559 is a division of application No. 12/199,797, filed on Aug. 27, 2008, granted, now 9,328,345.
Application 17/237,856 is a continuation of application No. 16/298,545, filed on Mar. 11, 2019, granted, now 11,015,195.
Application 16/298,545 is a continuation of application No. 15/081,559, filed on Mar. 25, 2016, granted, now 10,266,821, issued on Apr. 23, 2019.
Claims priority of provisional application 61/038,954, filed on Mar. 24, 2008.
Claims priority of provisional application 61/029,753, filed on Feb. 19, 2008.
Claims priority of provisional application 60/968,257, filed on Aug. 27, 2007.
Prior Publication US 2021/0301292 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); C12N 15/11 (2006.01)
CPC C12N 15/113 (2013.01) [C12N 15/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12N 2320/53 (2013.01); C12N 2330/51 (2013.01)] 27 Claims
 
1. An asymmetric interfering RNA duplex molecule for modulating expression of a target gene, comprising an antisense strand and a sense strand,
wherein the antisense strand is longer than the sense strand, has a length of 19, 20, 21, 22, 23, 24, 25, 26 or 27 nucleotides and includes a 3′-overhang of 1-9 nucleotides and a 5′-overhang of 0-8 nucleotides when duplexed with the sense strand;
wherein the sense strand has a length of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides and forms a double-stranded region with the antisense strand, and at least the first nucleotide and last nucleotide of the sense strand base pair with nucleotides of the antisense strand, and wherein the double-stranded region has a length of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 base pair; and
wherein the antisense strand is at least 70% complementary to an expressed nucleotide sequence of the target gene and the last nucleotide of its 3′ end is complementary to the target sequence.